Lucid Diagnostics Inc. (LUCD)
NASDAQ: LUCD · Real-Time Price · USD
1.280
+0.090 (7.56%)
At close: May 14, 2025, 4:00 PM
1.290
+0.010 (0.77%)
After-hours: May 14, 2025, 7:58 PM EDT
Lucid Diagnostics Revenue
Lucid Diagnostics had revenue of $828.00K in the quarter ending March 31, 2025, a decrease of -17.28%. This brings the company's revenue in the last twelve months to $4.17M, up 39.89% year-over-year. In the year 2024, Lucid Diagnostics had annual revenue of $4.35M with 79.00% growth.
Revenue (ttm)
$4.17M
Revenue Growth
+39.89%
P/S Ratio
17.32
Revenue / Employee
$57,958
Employees
72
Market Cap
132.43M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
LUCD News
- 9 hours ago - Lucid Diagnostics Inc. (LUCD) Q1 2025 Business Update Call Transcript - Seeking Alpha
- 14 hours ago - Lucid Diagnostics Provides Business Update and Reports First Quarter 2025 Financial Results - PRNewsWire
- 13 days ago - PAVmed to Hold a Business Update Conference Call and Webcast on May 15, 2025 - PRNewsWire
- 14 days ago - Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025 - PRNewsWire
- 20 days ago - NCI-Sponsored Study Shows Positive Data for Lucid Diagnostics' EsoGuard® Esophageal DNA Test in Patients Without Symptomatic GERD - PRNewsWire
- 4 weeks ago - Lucid Diagnostics: DNA Testing To Get Medicare Coverage, Driving Volumes, Says Bullish Analyst - Benzinga
- 4 weeks ago - Lucid Diagnostics Announces Closing of Public Offering of Common Stock - PRNewsWire
- 5 weeks ago - Lucid Diagnostics Announces Pricing of Public Offering of Common Stock - PRNewsWire